Endonovo Therapeutics (OTCMKTS:ENDVD – Get Free Report) and Qualigen Therapeutics (NASDAQ:AIXC – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, analyst recommendations and risk.
Institutional and Insider Ownership
3.2% of Qualigen Therapeutics shares are held by institutional investors. 5.6% of Endonovo Therapeutics shares are held by company insiders. Comparatively, 1.2% of Qualigen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Risk & Volatility
Endonovo Therapeutics has a beta of 1.98, indicating that its stock price is 98% more volatile than the S&P 500. Comparatively, Qualigen Therapeutics has a beta of 0.34, indicating that its stock price is 66% less volatile than the S&P 500.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Endonovo Therapeutics | $170,000.00 | 0.00 | -$400,000.00 | ($10.00) | N/A |
| Qualigen Therapeutics | N/A | N/A | -$6.26 million | ($7.50) | -0.13 |
Endonovo Therapeutics has higher revenue and earnings than Qualigen Therapeutics. Qualigen Therapeutics is trading at a lower price-to-earnings ratio than Endonovo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Endonovo Therapeutics and Qualigen Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Endonovo Therapeutics | -6,075.54% | N/A | -279.35% |
| Qualigen Therapeutics | N/A | N/A | -52.57% |
Analyst Recommendations
This is a breakdown of current ratings and target prices for Endonovo Therapeutics and Qualigen Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Endonovo Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
| Qualigen Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
Given Endonovo Therapeutics’ higher possible upside, equities research analysts plainly believe Endonovo Therapeutics is more favorable than Qualigen Therapeutics.
Summary
Endonovo Therapeutics beats Qualigen Therapeutics on 6 of the 11 factors compared between the two stocks.
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a biotechnology company, which engages in the development of bio-electronic approach to regenerative medicine. The firm also develops, manufactures and distributes evolutionary medical devices focused on the healing of wounds and reduction of pain, edema and inflammation on and in the human body. Its technology and products include Electroceuticals, EFECT Trial, SofPulse, Electroceutical Therapy, and Scientific Studies. The company was founded in November 2008 and is headquartered in Woodland Hills, CA.
About Qualigen Therapeutics
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient’s blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Receive News & Ratings for Endonovo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endonovo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
